Verastem/$VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
78
ISIN
US92337C2035
Website
Verastem Metrics
BasicAdvanced
$310M
-
-$3.50
0.85
-
Price and volume
Market cap
$310M
Beta
0.85
52-week high
$9.10
52-week low
$2.10
Average daily volume
2.2M
Financial strength
Current ratio
3.501
Quick ratio
3.306
Long term debt to equity
-227.441
Total debt to equity
-236.78
Interest coverage (TTM)
-36.17%
Profitability
EBITDA (TTM)
-131.041
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,488.77%
Operating margin (TTM)
-1,310.71%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-64.19%
Return on equity (TTM)
-2,159.52%
Valuation
Price to revenue (TTM)
23.997
Price to book
-8.95
Price to tangible book (TTM)
-8.95
Price to free cash flow (TTM)
-2.084
Free cash flow yield (TTM)
-47.98%
Free cash flow per share (TTM)
-270.63%
Growth
Earnings per share change (TTM)
-18.49%
3-year revenue growth (CAGR)
40.02%
3-year earnings per share growth (CAGR)
-10.79%
10-year earnings per share growth (CAGR)
-17.51%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Business Wire·2 weeks ago
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Business Wire·3 weeks ago
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $310M as of June 18, 2025.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of June 18, 2025.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.